Li Chen

Dr. Li Chen

Department of Respiratory and Critical Care Medicine, Peking University People’s Hospital, Beijing 100044, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2024 in European Respiratory Journal
Verified
Conference Paper
Closed access
LCLi Chen
Li Chen
JXJianbo Xue
Jianbo Xue
YWYu Wang
Yu Wang
ZGZhancheng Gao
Zhancheng Gao
Identifying the diagnosis as well as prognosis for patients presented with community-acquired pneumonia (CAP) remains challenging. We aimed to identify the role of lysophosphatidylcholine acyl-transferase (LPCAT) for CAP along with assessing this protein’s effectiveness as a biomarker for severity of disease and mortality. Prospective multicenter research study was carried out among hospitalized patients. A total of 299 CAP patients (including 97 severe CAP patients [SCAP]) and 20 healthy controls (HC) were included. A quantitative enzyme-linked immunosorbent test kit was employed for detecting the LPCAT level in plasma. We developed a deep-learning-based binary classification (SCAP or non-severe CAP [NSCAP]) model to process LPCAT levels and other laboratory test results. The level of LPCAT in patients with SCAP and death outcome was significantly higher than that in other patients. LPCAT showed the highest predictive value for SCAP. LPCAT was able to predict 30-day mortality among CAP patients, combining LPCAT values with PSI scores or CURB-65 further enhance mortality prediction accuracy. The on admission level of LPCAT found significantly raised among SCAP patients and strongly predicted SCAP patients but with no correlation to etiology. Combining the LPCAT value with CURB-65 or PSI improved the 30-day mortality forecast significantly.

6 March 2020 in Research Square
Verified
Preprint
Open access
PDF file
LCLi Chen
Li Chen
YZYali Zheng
Yali Zheng
LZLili Zhao
Lili Zhao
YZYing Zhang
Ying Zhang
LYLu Yin
Lu Yin
ZGZhancheng Gao
Zhancheng Gao
Background: This study aimed to characterize the lipidomic responses to community-acquired pneumonia (CAP), and validate the effectiveness of these lipids as indicators of the severity of the CAP as well as of the risk of death in severe CAP.Methods: Lipidomic profiles of serum were generated using ultra high-performance liquid chromatography with tandem mass spectrometry (UHPLC-MS/MS). Principal component analysis (PCA) and supervised orthogonal partial least squares discriminant analysis (OPLS-DA) was implemented to distinguish between the classes of samples and to identify the differentially expressed variables. The area under the receiver operating characteristic curve of the significant differential lipids was compared. Spearman’s rank correlation test and multiple linear regression (MLR) analysis were applied to further explore the putative differentially expressed lipids correlation with clinical parameters. Kaplan–Meier methods were used to build 30-day survival curves, and survival rates were compared using the log-rank test.Results: A total of 6 categories and 509 lipid species were detected in the positive ion mode using UPLC-MS/MS. In the negative ion mode, 3 categories and 195 lipid species were detected. According to the screening criteria, 5 lipids in total were selected as target lipids, which are PC (16:0_18:1), PC (18:2_20:4), PC (20:5_18:2), PC (36:4) and PC (38:6). Area under curves (AUC) for all five li p ids were superior to PSI (0.749, 0.550-0.892) and CURB-65 (0.772, 0.575-0.908). PC (18: 2_20: 4), PC (38: 6) and PC (36: 4) was negatively related to FiO 2 and PC (18: 2_20: 4) was inversely correlated with the PCT. As the relative abundance of PC (16:0_18:1), PC (36: 4), PC (20: 5_18: 2) and PC (38: 6) decreased, the length of hospital stay significantly extended. There was a statistically significant difference in the probability of 30-day mortality between the high-abundance and low-abundance groups of PC (16: 0_18: 1), PC (36: 4) and PC (20: 5_18: 2) (og-rank p <0.05).Conclusion: Our research suggests that the serum lipidomics approach of the UHPLC-MS/MS platform can be used to reveal lipid changes during CAP and establish lipid profiles related to disease severity.Trial registration: ClinicalTrials.gov, NCT03093220. Registered on 28 March 2017 (retrospectively registered).